These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 35746606)

  • 1. Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis.
    Huang YW; Qin A; Tsai CY; Chen PJ
    Viruses; 2022 May; 14(6):. PubMed ID: 35746606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
    Huang YW; Hsu CW; Lu SN; Yu ML; Su CW; Su WW; Chien RN; Hsu CS; Hsu SJ; Lai HC; Qin A; Tseng KC; Chen PJ
    Hepatol Int; 2020 Dec; 14(6):997-1008. PubMed ID: 33099752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
    Illés Á; Pinczés LI; Egyed M
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C.
    Hsu SJ; Yu ML; Su CW; Peng CY; Chien RN; Lin HH; Lo GH; Su WW; Kuo HT; Hsu CW; Yang SS; Yang SS; Tseng KC; Qin A; Huang YW; Chuang WL
    J Formos Med Assoc; 2021 Mar; 120(3):956-964. PubMed ID: 33077341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
    Wagner SM; Melchardt T; Greil R
    Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
    Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
    Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.
    Lo CC; Chuang WL; Kuo HT; Chen WM; Qin A; Tsai CY; Huang YW; Chen CY
    J Formos Med Assoc; 2024 Jan; 123(1):55-61. PubMed ID: 37666718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
    Chen CY; Chuang WL; Qin A; Zhang WH; Zhu LY; Zhang GQ; Chen JJ; Lo CC; Zhou X; Mao X; Shang J; Kuo HT; Xie W; Chen CH; Lo GH; Jun DW; Dang S; Tsai CY; Wang TF; Lai HH; Tseng KC; Huang YW; Chen PJ
    JGH Open; 2022 Nov; 6(11):782-791. PubMed ID: 36406648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.
    Lin HH; Hsu SJ; Lu SN; Chuang WL; Hsu CW; Chien RN; Yang SS; Su WW; Wu JC; Lee TH; Peng CY; Tseng KC; Qin A; Huang YW; Chen PJ
    JGH Open; 2021 Aug; 5(8):929-940. PubMed ID: 34386602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
    Gisslinger H; Zagrijtschuk O; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Kralovics R; Gisslinger B; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Schalling M; Them NC; Kadlecova P; Klade C; Greil R
    Blood; 2015 Oct; 126(15):1762-9. PubMed ID: 26261238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-efficacy and exposure-safety analyses of ropeginterferon alfa-2b treatment in patients with polycythaemia vera.
    Qin A; Wu D; Li Y; Zhang J; Wang W; Shen W; Liao J; Lin S; Chang C; Chen H; Cui J; Su X
    Br J Clin Pharmacol; 2024 Jun; 90(6):1493-1502. PubMed ID: 38500445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b.
    Shimoda K; Qin A; Komatsu N; Kirito K
    Int J Hematol; 2024 Aug; 120(2):151-156. PubMed ID: 38951434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration.
    Miyachi N; Zagrijtschuk O; Kang L; Yonezu K; Qin A
    Clin Drug Investig; 2021 Apr; 41(4):391-404. PubMed ID: 33725322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of Action of Ropeginterferon Alfa-2b in Polycythemia Vera Treatment.
    Qin A
    Clin Ther; 2024 May; 46(5):439-440. PubMed ID: 38697872
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferons for the treatment of chronic hepatitis C infection.
    Luxon BA; Grace M; Brassard D; Bordens R
    Clin Ther; 2002 Sep; 24(9):1363-83. PubMed ID: 12380630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
    Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
    Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
    Kiladjian JJ; Marin FF; Al-Ali HK; Alvarez-Larrán A; Beggiato E; Bieniaszewska M; Breccia M; Buxhofer-Ausch V; Cerna O; Crisan AM; Danaila CD; De Stefano V; Döhner K; Empson V; Gora-Tybor J; Griesshammer M; Grosicki S; Guglielmelli P; García-Gutierrez V; Heidel FH; Illés A; Tomuleasa C; James C; Koschmieder S; Krauth MT; Krejcy K; Lazaroiu MC; Mayer J; Nagy ZG; Nicolini FE; Palandri F; Pappa V; Reiter AJ; Sacha T; Schlager S; Schmidt S; Terpos E; Unger M; Wölfler A; Cirici BX; Klade C
    Ann Hematol; 2024 Jul; 103(7):2299-2310. PubMed ID: 38438627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
    Huang YW; Qin A; Fang J; Wang TF; Tsai CW; Lin KC; Teng CL; Larouche R
    Br J Clin Pharmacol; 2022 May; 88(5):2396-2407. PubMed ID: 34907578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
    Barbui T; Vannucchi AM; De Stefano V; Masciulli A; Carobbio A; Ferrari A; Ghirardi A; Rossi E; Ciceri F; Bonifacio M; Iurlo A; Palandri F; Benevolo G; Pane F; Ricco A; Carli G; Caramella M; Rapezzi D; Musolino C; Siragusa S; Rumi E; Patriarca A; Cascavilla N; Mora B; Cacciola E; Mannarelli C; Loscocco GG; Guglielmelli P; Betti S; Lunghi F; Scaffidi L; Bucelli C; Vianelli N; Bellini M; Finazzi MC; Tognoni G; Rambaldi A
    Lancet Haematol; 2021 Mar; 8(3):e175-e184. PubMed ID: 33476571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.